2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1214

Fracture Incidence and Characteristics in Young Adults Age 18 to 49 Years: A Population-Based Study
Abstract Number: 2383

Frailty and Risk of Fractures in Patients with Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)
Abstract Number: 585

Frequencies of Ligament Ossification in Patients with Ankylosing Spondylitis According to Several Ligaments Around Spine By Whole Spine CT Scan
Abstract Number: 274

Frequency of Chronic Joint Pain Following Chikungunya Infection: A Colombian Cohort Study
Abstract Number: 2307

Frequency of Comorbidities in Patients with Juvenile Ideopathic Arthritis – Results of an Observational Cohort Study
Abstract Number: 154

Frequency of Fibromyalgia in Patients with Antiphospholipid Syndrome. a Cross-Sectional Study
Abstract Number: 2594

Frequency of Infusions Among Patients Diagnosed with Systemic Lupus Erythematosus Initiating Treatment with Intravenous Belimumab
Abstract Number: 308

Frequency, Morbidity and Healthcare Utilization of Diffuse Idiopathic Skeletal Hyperostosis (DISH) Patients at a University Hospital
Abstract Number: 302

From Monocytes to Macrophages: the Pathogeneses of Spontaneous Inflammatory Arthritis in CD11c-Flip-KO (HUPO) Mice
Abstract Number: 2926

Fucosyltransferase-1 Mediates Macrophage Driven Myofibroblast Differentiation and TGF-β Signaling in Systemic Sclerosis and Bleomycin-Induced Fibrosis
Abstract Number: 2248

Function, Pain, Fatigue, and Participation Are the Primary Contributors to the Patient Global Assessment in Rheumatoid Arthritis
Abstract Number: 79

Functional Analysis of the Novel G58V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS)
Abstract Number: 2589

Functional and Mechanistic Characterization of Anifrolumab, a Fully Human Monoclonal Antibody Targeting the Interferon Alpha Receptor 1 for the Treatment of SLE
Abstract Number: 2171

Functional Measures and Patient Home Self-Assessments in the Idiopathic Inflammatory Myopathies
Abstract Number: 658

Functionally Active MAIT Cells in Psoriatic Arthritis: A New Member of the IL-23/IL-17 Cytokine Network

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].